IMF Chief Says Global Economy Facing Sharp Decline, Difficult Journey

Director-General of the International Monetary Fund (IMF) Kristalina Georgieva. Asharq Al-Awsat
Director-General of the International Monetary Fund (IMF) Kristalina Georgieva. Asharq Al-Awsat
TT

IMF Chief Says Global Economy Facing Sharp Decline, Difficult Journey

Director-General of the International Monetary Fund (IMF) Kristalina Georgieva. Asharq Al-Awsat
Director-General of the International Monetary Fund (IMF) Kristalina Georgieva. Asharq Al-Awsat

Director-General of the International Monetary Fund (IMF) Kristalina Georgieva has expressed concern that the global economy was facing a severe decline and a difficult journey despite the tremendous efforts of the G20 to promote policies that restore confidence in pluralism, overcome the pandemic with minimal losses, while working to improve people’s lives, empower women and create greener and fairer economies.

In an interview with Asharq Al-Awsat, Georgieva revealed a study of a package of options to further adapt the IMF’s lending toolkit to support eligible countries. She noted that by the end of 2020, expectations point to a global economic contraction by 4.4 percent – a bit lower than early 2020 estimates.

But she warned that the world was still facing the worst recession since the Great Depression, adding that the road ahead would be steep and the journey difficult.

The IMF director said that the partial recovery achieved so far was due to extraordinary measures to address the health crisis and protect the economy. She explained that G20 governments have provided around $12 trillion in financial support to families and businesses.

Unprecedented monetary policy measures kept the credit flowing, she underlined, which helped millions of companies stay in business.

On poor countries, the IMF Director said that access to financing remained difficult, adding that the Fund expects the recovery to be partial and uncertain, because there is currently no final remedy to the health crisis.

According to Georgieva, health measures remain a top priority, along with concerted global efforts to secure vaccines and treatments for a permanent exit from the epidemic, pointing out that until then, policymakers must avoid early withdrawal of financial and monetary support to prevent a wave of bankruptcies and unemployment.

On her expectations regarding the reopening of the European economy, she noted that recent IMF estimates for Europe indicated that GDP would decline by 7% in 2020. As in the global economy, a partial and uneven recovery is expected, while real GDP is estimated to recover by 4.7% in 2021.

Georgieva stressed that the Europeans have acted very decisively to mitigate the effects of the external shock, as fiscal measures were estimated at 6 percent of GDP for advanced European economies and 3 percent of GDP for emerging economies.

She pointed out that the unprecedented political response to the health crisis prevented a much worse outcome, saying that at least 54 million jobs were supported through furlough plans in Europe.

Nevertheless, Georgieva pointed to great risks in the future, especially because the course of the epidemic remains uncertain, and the second wave of infections intensifies in Europe.

Regarding the role of the IMF in the coronavirus pandemic, she said the Fund was the center of the global financial safety net.

Georgieva said that since the beginning of the outbreak, the IMF has provided more than $100 billion in funding to 81 countries, including 48 low-income states. In addition, the Fund worked to strengthen the members’ ability to benefit from emergency funding and expanded increased access until 2021.

She also revealed that the IMF was studying a package of options to further adapt the Fund’s lending toolkit to support countries at this moment of extreme uncertainty.

Georgieva said the IMF was ready to help members move forward in a post-pandemic world by investing in people, the digital economy and the green economy.



Hevolution CEO Discusses Career in Innovation, Medicine, and Business

Dr. Mehmood Khan, CEO of the Hevolution Foundation
Dr. Mehmood Khan, CEO of the Hevolution Foundation
TT

Hevolution CEO Discusses Career in Innovation, Medicine, and Business

Dr. Mehmood Khan, CEO of the Hevolution Foundation
Dr. Mehmood Khan, CEO of the Hevolution Foundation

Dr. Mehmood Khan, CEO of the Hevolution Foundation, the largest philanthropy organization funding aging medicine in the world, expressed that receiving Saudi citizenship will boost his scientific and practical capabilities.
He said this new status will help him advance his research, especially in addressing aging.
This comes as part of a recent royal decree granting Saudi citizenship to several notable scholars, doctors, researchers, and innovators.
“Our Chairman, his Royal Highness (Crown Prince Mohammed bin Salman), has very high expectations of our work and the impact we need to do; We were created in part because of his vision,” Khan told Asharq Al-Awsat.
“Living up to the expectations and challenges we get faced with is itself exciting, but it is challenging,” revealed Khan, affirming that Hevolution’s team is “up to that task.”
Khan, who has experience in both corporate and medical fields, told Asharq Al-Awsat that his work across academic, public, and private sectors has been a continuous learning process, with each area enhancing the others.
According to the CEO, these industries are interconnected, and combining their strengths often leads to the best solutions.
This insight inspired the Hevolution initiative, which brings together the scientific community, NGOs, pharmaceutical companies, policymakers, academia, biotech firms, CEOs, and others to promote healthy aging.
Khan highlighted the value of integrating insights from different sectors.
Academia provides detailed research, the public sector offers insights on population health and regulations, and the corporate world brings innovation and efficiency, explained Khan, adding that by merging these perspectives, the world can tackle complex health challenges more effectively.
“We’ve been working through, and are now investing, funding and partnering with over 200 scientists around the world, and over 150 different university labs,” said Khan.
Hevolution uses this integrated approach to advance healthy aging.
This initiative embodies my passion for addressing major challenges and offers a significant opportunity to make a global impact.
Khan talked about the first $400 million commitment Hevolution made in the last 23 months, calling it “unprecedented.”
“There has never been a non-profit organization in the world that has gone from not existing to now becoming the largest philanthropy funding aging biology and medicine in the world,” affirmed Khan.
Khan stressed that work at Hevolution not only pushes scientific boundaries but also promotes cross-sector collaboration to improve global health outcomes.
Since Khan’s early days in medical school, he’s been deeply interested in nutrition and population health, which was an unconventional focus back then. This journey set the foundation for his later work in community health.
Khan’s time as an endocrinology faculty member at the Mayo Clinic was crucial. He led programs on diabetes, endocrine diseases, metabolism, and nutrition, which strengthened his expertise in designing disease prevention systems.
In the private sector, Khan took on a key role at Takeda Pharmaceutical as the global head of R&D, which shaped his approach to innovative healthcare solutions.
At PepsiCo, as Chief Scientific Officer, he learned crucial principles of scale, impact, transformation, and tackling global challenges.
As CEO of Hevolution, Khan uses all his professional experience to advance the foundation’s mission of developing health sciences to address age-related diseases.
Khan serves on the boards of Reckitt Benckiser and the Saudi Research, Development, and Innovation Authority (RDIA).
He is the CEO of Life Biosciences, a member of Saudi Arabia’s biotechnology strategy committee, and the chair of the advanced technology visiting committee at the US National Institute of Standards and Technology (NIST).
Khan told Asharq Al-Awsat that he feels honored to have recently become a Saudi citizen by royal decree, while also holding dual US and UK citizenship. This helps him lead Hevolution effectively and work closely with international partners.
Khan commented on his recent Saudi citizenship, saying that in addition to feeling honored to receive Saudi citizenship by royal decree, alongside other distinguished individuals, this recognition is a great privilege.
Being a Saudi citizen, as per Khan, is a significant milestone and acknowledges the progress in his work in aging science and global health. It also strengthens Khan’s commitment to the work at Hevolution.
Khan noted that this new status enhances his ability to build relationships and collaborate within the Kingdom and internationally. It offers a deeper connection with the local community and better opportunities to engage with policymakers and leaders.
He also said that this recognition boosts Hevolution’s global presence and credibility, making the foundation’s collaborations with international scientists and business leaders stronger. It positions Hevolution as a key player in addressing age-related diseases.
Khan emphasized that this honor reflects the hard work and innovation of Hevolution’s entire team.
The CEO said that it was collective efforts that have made this achievement possible.
Khan also said he is excited to engage more deeply with the scientific and medical community in the Kingdom, adding that his new citizenship helps him contribute to Vision 2030 and the national biotechnology strategy, promoting innovation and attracting top global talent.